Gastrocon500 mg+100 mg

Gastrocon is indicated for the symptomatic relief of conditions associated with gastro-oesophageal reflux, such as heartburn and acid regurgitation, particularly when these occur secondary to reflux of stomach acid, bile, and pepsin into the oesophagus.

Established / Guideline-Supported Uses

• Heartburn and acid regurgitation associated with gastro-oesophageal reflux disease (GERD)
• Indigestion (dyspepsia) related to acid reflux
• Reflux oesophagitis, as symptomatic adjunct therapy
• Reflux symptoms occurring during pregnancy
• Reflux symptoms associated with hiatus hernia
• Symptoms of laryngopharyngeal reflux, such as hoarseness, chronic cough, and sore throat, particularly after gastric surgery

Important Note

Gastrocon provides short-term symptomatic relief and is not a substitute for medical evaluation. If symptoms are severe, persistent beyond 7 days, or associated with alarm features such as unintentional weight loss, difficulty swallowing (dysphagia), vomiting blood, or black/tarry stools (suggesting gastrointestinal bleeding), a physician should be consulted promptly for further investigation.

Each unit of Sodium Alginate + Potassium Bicarbonate typically contains Sodium Alginate and Potassium Bicarbonate in a fixed-dose combination, commonly formulated as approximately 500 mg Sodium Alginate with 100 mg Potassium Bicarbonate per tablet or per 5 mL of oral suspension. Exact strengths vary by brand and dosage form; always check the product label for the specific composition dispensed.

Gastrocon is a fixed-dose combination antacid preparation belonging to the alginate-based, raft-forming class of gastro-oesophageal reflux therapies. Unlike conventional antacids that simply neutralise stomach acid, Gastrocon works through a distinct physical mechanism: upon contact with gastric acid, the alginate component forms a viscous gel that is converted into a floating, foam-like "raft" by carbon dioxide bubbles generated from the bicarbonate component.

This raft floats on top of the stomach contents, at the gastro-oesophageal junction, acting as a mechanical barrier that reduces the reflux of acid, bile, and pepsin into the oesophagus. Gastrocon is available as chewable tablets and oral suspension, and is widely used for the short-term relief of heartburn, acid regurgitation, and indigestion, including reflux symptoms occurring during pregnancy.

Gastrocon belongs to the therapeutic class of antacids and alginate-based anti-reflux (raft-forming) agents, used for the symptomatic management of gastro-oesophageal reflux disease and related upper gastrointestinal symptoms.

Sodium Alginate + Potassium Bicarbonate acts through a physical, non-systemic mechanism rather than classical acid neutralisation or acid-secretion inhibition.

Mechanism of Action

• On contact with gastric acid, the sodium alginate component undergoes a rapid reaction to form a cohesive, viscous alginate gel.
• The potassium bicarbonate component reacts with gastric acid to liberate carbon dioxide gas, and these tiny bubbles become entrapped within the alginate gel matrix.
• The gas-entrapped gel becomes less dense than gastric contents and rises to float on top of the stomach contents as a continuous, coherent layer known as the "raft."
• This raft preferentially localises at the gastro-oesophageal junction (the "acid pocket"), forming a mechanical barrier that physically impedes the reflux of acidic gastric contents, bile, and pepsin into the oesophagus.
• Because the raft floats above the stomach contents rather than mixing with them, it can continue to protect against reflux even when unbuffered acid is still present in the stomach below.

Sodium Alginate + Potassium Bicarbonate acts locally within the gastrointestinal tract; systemic absorption of the alginate component is minimal, and its effect is largely mechanical/physical rather than pharmacological in the systemic sense. The protective raft generally persists for several hours before being gradually broken down and cleared from the stomach.

Gastrocon chewable tablets should be chewed thoroughly before swallowing. The oral suspension should be shaken well before each dose and measured using an appropriate measuring device. Gastrocon is best taken after meals and at bedtime, and should be separated by at least 2 hours from other oral medicines to avoid reduced absorption of those medicines.

Gastrocon can physically bind to or coat certain co-administered oral drugs in the gastrointestinal tract, or alter local gastric pH, thereby reducing their absorption and clinical effectiveness.

Clinically Significant Interactions

• Tetracyclines and fluoroquinolone antibiotics (e.g. doxycycline, ciprofloxacin): absorption may be significantly reduced, potentially reducing antibiotic efficacy.
• Oral iron salts: chelation-type interaction reduces iron absorption.
• Thyroid hormone replacement (levothyroxine): absorption may be reduced, risking under-treatment of hypothyroidism.
• Chloroquine: absorption may be reduced.
• Oral bisphosphonates: absorption is already low and may be further reduced.
• Estramustine: absorption may be reduced.

Recommendation: Separate administration of Gastrocon from other oral medicines by at least 2 hours, whenever possible, to minimise the risk of reduced drug absorption.

Gastrocon is generally well tolerated. Reported adverse effects are usually mild and infrequent.

• Nausea
• Constipation
• Diarrhoea
• Headache
• Bloating or abdominal distension sensation, more commonly with excessive dosing
• Rarely, hypersensitivity reactions (e.g. rash, itching)

Patients should seek medical advice if side effects are severe or persistent.

Pregnancy: Gastrocon may be used during pregnancy for the relief of reflux symptoms when clinically indicated, as it is believed to act largely locally within the gastrointestinal tract with minimal systemic absorption. However, as with any medicine in pregnancy, it should be used only if clearly needed, at the lowest effective dose, and after consultation with a physician, since comprehensive controlled safety data are limited.

Lactation: Gastrocon is generally considered compatible with breastfeeding, with no known adverse effects reported in breastfed infants, given its predominantly local, non-systemic action. Nonetheless, a physician or pharmacist should be consulted before use during breastfeeding, particularly with prolonged or frequent use.

Gastrocon should be used with caution in the following situations:

• Renal impairment: Because Gastrocon contains potassium and sodium, patients with significant renal impairment are at increased risk of hyperkalaemia and sodium accumulation; use only under medical supervision, especially in patients on a salt-restricted or potassium-restricted diet.
• Congestive cardiac failure: The sodium content may contribute to fluid retention; use with caution in patients on a sodium-restricted diet for heart failure.
• Hypercalcaemia, nephrocalcinosis, or recurrent calcium-containing kidney stones: Use with caution, as some alginate/antacid formulations contain calcium-based excipients that could theoretically aggravate these conditions; check the specific product's full excipient list.
• Reduced gastric acid states: Effectiveness of Gastrocon depends on a reaction with gastric acid to form the protective raft; efficacy may be reduced in patients with very low gastric acid production (e.g. those on high-dose acid-suppressing therapy or with achlorhydria).
• Persistent or alarm symptoms: Gastrocon is intended for short-term symptomatic relief. Medical review is advised if symptoms persist beyond 7 days, recur frequently, or are accompanied by alarm features such as weight loss, dysphagia, or gastrointestinal bleeding, as these may indicate a more serious underlying condition requiring further evaluation.

Overdose with Gastrocon is rare given its physical, largely non-systemic mechanism of action. Excessive intake may cause an exaggerated bloating or abdominal distension sensation due to excess carbon dioxide/gel formation, and theoretically could contribute to sodium or potassium imbalance in susceptible individuals (e.g. significant renal impairment) with very high or prolonged overuse. If overdose is suspected, seek immediate medical attention or contact a poison control center; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Children

Gastrocon is not recommended for children under 2 years of age, as safety and efficacy have not been established in this age group. Reduced doses are used for children aged 2-12 years, based on formulation (see Dosage and Administration). Children over 12 years may use adult dosing.

Elderly

No dose adjustment of Gastrocon is required in elderly patients based on age alone; however, elderly patients frequently have coexisting renal impairment or are on multiple medications, so caution regarding drug interactions and renal function is advised.

Renal Impairment

Use Gastrocon with caution in patients with significant renal impairment, particularly those on a restricted-salt diet, due to the sodium and potassium content of the combination (see Precautions and Warnings).

Hepatic Impairment

No dose adjustment of Gastrocon is required in hepatic impairment.

Gastrocon is generally intended for short-term, as-needed symptomatic relief. If symptoms do not improve or continue to recur after 7 days of regular use, treatment should be reviewed by a physician to exclude other underlying causes and to consider alternative or additional therapy.

Antacid; Alginate-based raft-forming anti-reflux agent

Sodium Alginate + Potassium Bicarbonate works by a physical raft-forming mechanism: sodium alginate reacts with gastric acid to form a gel, while potassium bicarbonate releases carbon dioxide that becomes trapped within this gel, causing it to float as a protective "raft" over the stomach contents at the gastro-oesophageal junction, mechanically reducing reflux of acid, bile, and pepsin into the oesophagus.

Gastrocon may be used in children aged 2 years and above for symptomatic relief of reflux-related heartburn and indigestion, using age-appropriate reduced doses of the oral suspension or chewable tablet formulation (see Dosage and Administration). Gastrocon is not recommended for children under 2 years of age, as safety and efficacy have not been established in this age group. Parents should consult a physician before use in young children, especially if symptoms are frequent, severe, or associated with poor feeding or growth.